

Osteoporosis Management in Women Who Had a Fracture (OMW) Measure

Measure Description

The percentage of women 67–85 years of age who suffered a fracture and who had either a bone mineral density (BMD) test or prescription for a drug to treat osteoporosis in the six months after the fracture.

- The measure is a weight of (0.5) star and is part of the **STARs P4P Incentive Program**.
- Members are included in the measure if they've suffered a fracture during the 12-month window that begins on July 1st of the year prior to the measurement year and ends on June 30th of the measurement year.

Exclusions

- Members who had a BMD Test conducted during the 730 days (24 months) prior to the fracture.
- Members who had a claim/encounter for osteoporosis therapy during the 365 days (12 months) prior to the episode date.
- Members who were dispensed an osteoporosis medication during the 365 days (12 months) prior to the fracture.
- Members in hospice or using hospice services.
- Members who received palliative care.

Member Compliance

- Test the patient for osteoporosis via a BMD test within 180 days of the fracture date.
- Treat the patient with an osteoporosis medication within 180 days of the fracture date.
- Ensure member did not have osteoporosis therapy 12 months prior to the episode date.
- Members in hospice or using hospice services.
- Members who received palliative care.

Call to Action

- Schedule fracture patients for a BMD test or prescribe an osteoporosis medication within 180 days of the fracture.
- Ensure all patients are being tested for osteoporosis yearly via a BMD test to prevent fractures and the development of osteoporosis whenever possible.
- Ensure patients fill their prescription for an osteoporosis medication at a pharmacy.

Osteoporosis Therapies & Medications

Drug Classification	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5
Bisphosphonates	Alendronate (QL)	Ibandronate (QL)	Risedronate (QL)		
Selective Estrogen Receptor Blocker		Raloxifene (QL)			Teriparatide (QL)
Rank Ligand Inhibitors				Denosumab (QL)	Denosumab (PA; QL)
Hormones Analog					Abaloparatide (PA; DL; QL) Teriparatide (PA; DL; QL)